HER3 expression and MEK activation in non-small-cell lung carcinoma.

Pub Date : 2021-04-09 DOI:10.2217/lmt-2020-0031

Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Chloe Baker, Mary O'Brien, Jaishree Bhosle, Sanjay Popat, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom

{"title":"HER3 expression and MEK activation in non-small-cell lung carcinoma.","authors":"Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Chloe Baker, Mary O'Brien, Jaishree Bhosle, Sanjay Popat, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom","doi":"10.2217/lmt-2020-0031","DOIUrl":null,"url":null,"abstract":"Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression.Materials & methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA).Results: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression.Conclusion: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/37/lmt-10-48.PMC8162178.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression.

Materials & methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA).

Results: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression.

Conclusion: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.

Abstract Image

查看原文

HER3在非小细胞肺癌中的表达和MEK的激活。

目的:探讨HER3在肺腺癌(adeno-NSCLC)中的表达，并确定HER3表达的潜在机制。材料与方法:对45例腺非小细胞肺癌患者的肿瘤标本进行分析。利用肿瘤基因组图谱(TCGA)的免疫组织化学和生物信息学方法鉴定HER3和HER2的表达。结果:HER3在42.2%的病例中高表达。ERBB3拷贝数不能解释HER3过表达。TCGA的生物信息学分析表明，MEK活性评分(功能信号的替代指标)与HER3配体无关。调整EGFR表达后，ERBB3 RNA表达水平与MEK活性显著相关。结论:HER3表达是常见的，并且由于频繁的过表达和功能性下游信号传导是潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文